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Abstract
Many dental patients complain of oral symptoms after dental treatment, such as chronic pain or occlusal
discomfort, for which the cause remains undetermined. These symptoms are often thought to be mental or
emotional in origin, and patients are considered to have an “oral psychosomatic disorder”. Representative medically
unexplained oral symptoms/syndromes (MUOS) include burning mouth syndrome, atypical odontalgia, phantom
bite syndrome, oral cenesthopathy, or halitophobia. With an increasing prevalence of these MUOS, dentists are
being asked to develop new approaches to dental treatment, which include taking care of not only the patient’s
teeth but also the patient’s suffering. Progress in the understanding of mind-body interactions will lead to
investigations on the pathophysiology of MUOS and the development of new therapeutic approaches.
Keywords: Psychosomatic dentistry, Medically unexplained oral symptoms, Burning mouth syndrome, Atypical
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Background
Many dental patients complain of oral symptoms after
dental treatment, such as chronic pain or occlusal dis-
comfort, for which the cause remains undetermined [1].
Such symptoms are often thought to be mental or emo-
tional in origin, and patients are considered to have an
“oral psychosomatic disorder” [2]. The clinical need for
a psychosomatic approach has been acknowledged for
over 100 years by Japanese dentists. However, the mech-
anical and surgical aspects of dentistry have impeded the
development of such an approach. Dentists have inher-
ent difficulties with oral symptoms of undetermined
etiology, including toothaches of unknown origin. We
tend to look for the most likely cause and repeat inef-
fective dental treatments that fail to relieve the patient’s
symptoms. We finally conclude that the pain “must be
psychogenic” and try to avoid patients with psychogenic
pain. The Japanese health care insurance system, which
only covers conventional dental problems, has contrib-
uted to the tendency of dentists to avoid patients with
unexplained dental pain, in part because of economic
reasons.
Some Japanese dentists have decided to specialize in
psychosomatic dentistry. Fortunately, because of increas-
ing knowledge about brain functions, there has been some
progress in understanding the mind-body interactions. In
2015, the theme of the 30th anniversary meeting of the
Japanese Society of Psychosomatic Dentistry was “From
Brain to Dentistry”.
In this article, we introduce psychosomatic problems in
dentistry by describing representative “oral psychosomatic
disorders” and discuss possible future developments in
this field.
Medically unexplained oral symptoms (MUOS)
Patients who complain of physical symptoms without
identifiable etiologies are common in clinical medical
practice [3]. Such symptoms are known as medically un-
explained symptoms (MUS) and are problematic for many
physicians.
In oral medicine, many dentists encounter very similar
problems. The most typical symptom is chronic oral pain
with “nothing the matter” [4], which is a manifestation of
burning mouth syndrome (BMS) [5] and atypical odontal-
gia (AO) [6]. Complaints about dental occlusion are pecu-
liar to dentistry. Dry mouth or disturbances in taste and
salivation may be common problems that other specialists
such as otolaryngologists see.
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Dentists tend to overtreat these patients, and excessive or
unnecessary dental procedures may worsen them (Fig. 1).
Orthopedic surgeons who treat chronic low back pain may
encounter similar situations. In the absence of an effect-
ive management strategy, the patient’s atypical illness,
along with help-seeking behaviors and worries about
an unrecognized illness, persist, while frustration and
tensions escalate between the dentist and patient [4].
The problems of these patients have been called “oral
psychosomatic disorders”; but because of the implication
that the problem is “psychogenic”, patients are reluctant
to accept the diagnosis. Therefore, the use of another
term, “medically unexplained oral symptoms” (MUOS)
is preferable. We have reported that the estimated preva-
lence of MUOS among dental patients ranges from 5 to
10 % or more [2]. Representative MUOS are shown in
Table 1.
Chronic oral pain
The impact of chronic oral pain on quality of life should
not be ignored [7, 8]. BMS and AO are both chronic
pain disorders that occur in the absence of any organic
cause, and they are often regarded as psychogenic condi-
tions. Although many studies have been performed on
the relationship between oral pain and psychological
factors, the nature of the relationship remains unclear
[9–12]. Few patients with chronic oral pain are treated
by psychiatrists [13].
BMS is characterized by a burning sensation involving
the tongue or other oral sites, usually in the absence of
clinical and laboratory findings [5]. Delays in the diagno-
sis, referral, and appropriate management of BMS patients
are frequent [14]. Patients with BMS are often finally told
that “nothing is wrong” [4], even though they have severe
pain and have not received any effective treatment. They
become frustrated, very anxious, and worried about accru-
ing debt for serious diseases such as oral cancer.
BMS is a syndrome that is manifested by not only pain,
but also by many other intra and/or extra oral discomforts
[15, 16], including sore mouth, sensation of dry mouth
without hyposalivation, and loss of taste or changes in
taste, such as a bitter or metallic tastes.
Medications that act in the brain, such as benzodiaze-
pines, tricyclic antidepressants (e.g., amitriptyline), and
anticonvulsants (clonazepam) are known to be effective
for patients with BMS [17]. SNRIs [18] and SSRIs [19]
are also reported to be effective for BMS. Burning
mouth pain usually responds to lower dosages in the
recommended ranges [5]. Some patients also appear to
respond better to low-dose combinations of these medi-
cations [17]. But because of the heterogeneity of the
pharmacological effects of these drugs, patients have var-
ied responses and a variety of side effects, which hinder
dentists in providing adequate prescriptions.
Whether the peripheral or central nervous system un-
derlies BMS remains controversial [20]. Evidence from
various clinical and brain imaging studies [21, 22] should
enable the subdivision of patients into treatment sub-
groups based on underlying neurological involvement.
Compared to BMS, AO is not as commonly seen in
other medical settings, and it has received substantial
attention from dentists in recent years [5, 23]. The Inter-
national Association for the Study of Pain defines AO as
severe throbbing pain in a tooth without major pathology.
Ineffective treatment of this type of chronic dental pain
often is considered to be treatment failure, which results
in repeated, ineffective dental treatments to relieve the
pain, such as dental filling, root canal, or even extraction.
The resulting iatrogenic changes to the treated tooth leads
to difficulty in performing further diagnostic evaluations.
The lack of knowledge about the pathophysiologic
mechanisms of these pain conditions is a major reason
for problems in their diagnosis and management [20].
The underlying pathophysiologic mechanism seems to
be neural dysfunction triggered by some type of dental
or oral manipulation that involves the peripheral sensory
nerves or the region of the brain that processes the
sensation of oral pain.
Amitriptyline is one of the more commonly prescribed
tricyclic medications for AO [23]. Because of the many
Fig. 1 Panoramic radiograph of a patient with phantom bite
syndrome. Several dentists had treated a 40-year-old woman for her
malocclusion over many years, performing not only prosthodontic
procedures but also orthognathic surgery on her mandible. No one
was able to treat her to her satisfaction
Table 1 Medically Unexplained Oral symptoms/syndromes
(MUOS)
1. Burning Mouth Syndrome (BMS) a
2. Atypical Odontalgia (AO)
3. Oral Cenesthopathy (Oral Dysesthesia)
4. Halitophobia (Olfactory reference syndrome)
5. Occlusal dyscomfort (Phantom Bite Syndrome)
6. Odontophobia (Dental Phobia)
aBMS includes dry mouth and dysgeusia
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side effects and varied responses to this drug, very few den-
tists prescribe it. Although psychotherapy may be needed
in some cases, in many cases it alone does not result in
satisfactory improvement. Dental education should add
additional training on the pharmacotherapies for AO.
Although BMS and AO both manifest as chronic oral
pain, they differ in other clinical characteristics. For ex-
ample, the mean age of patients with AO is significantly
lower than the mean age of BMS patients, which indi-
cates possible differences in biologic background [11].
However, for the pathophysiologic mechanisms under-
lying the chronic oral chronic pain of both BMS and
AO, ongoing basic investigations in dentistry are focused
on the peripheral (trigeminal) nerves [24, 25].
Occlusal discomfort
Occlusal discomfort is a problem unique to dentistry, and
some patients irritate their dentists because of their unrea-
sonable complaints, demands, and incomprehensible
claims concerning dental treatment. Phantom bite syn-
drome (PBS) is characterized by a persistent, uncomfort-
able sensation of occlusion without any evidence of
occlusal discrepancy [26–28]. PBS is also called “occlusal
discomfort” or “occlusal dysesthesia” [29, 30]. Patients
complain that their occlusion is “wrong”, “somewhat high/
low”, or “the bite is off.” They visit multiple dentists seek-
ing “bite correction” because of their strong belief in den-
tal treatment, regardless of the risk of exacerbating their
symptoms (Fig. 2) [31]. Various MUS, including headache,
dizziness, shoulder stiffness, low back pain, and fatigue,
often accompany PBS and worsen after even minor dental
adjustments, which the patients have requested [32].
Because of the ineffectiveness of repeated occlusal adjust-
ments, PBS has been regarded to be a psychiatric disorder
related to paranoia, personality disorder [27], or somato-
form disorder. Some investigators recently proposed that
brain dysfunctions might be involved [1, 32, 33].
Most patients with PBS do not have severe psychiatric
comorbidities [31]. Watanabe, et al. [31] reported that the
frequency of psychiatric comorbidities was significantly
lower in PBS occurring with a dental trigger than in PBS
without a specific trigger. In addition, patients without a
psychiatric comorbidity showed significantly better out-
comes than those with a psychiatric comorbidty. After
useless dental treatment is stopped [32], antidepressants
or aripiprazole may be effective for managing the symp-
toms of patients with PBS. In addition to clinical studies,
brain-imaging studies are expected to clarify the patho-
physiology of PBS [34].
Disturbances in oral sensations
A notable number of patients visit dentists because of un-
usual oral sensations without evident cause. Patients com-
plain of abnormal sensations such as excessive mucus
secretion, slimy sensation in the mouth, or a feeling of a
foreign body in the mouth, without corresponding patho-
logical findings in the oral cavity. This disorder is called
“oral cenesthopathy” [35].
Because of their firm conviction that their annoying
symptoms have a somatic basis, the patients with oral cen-
esthopathy often visit dental clinics rather than consulting
a psychiatrist. To make matters worse, the symptoms in
most cases are resistant to drug treatment, which results
in dentist shopping [36].
For patients with oral cenesthopathy, strategic
compartmentalization among medical specialists and
regional medical collaborative platforms may be useful,
because this approach can consider complaints about
other organs, comorbid psychiatric disorders, and the
resulting disabilities of these patients. Progress in brain
imaging studies [36–38] and development of a tool for
assessing psychosomatic symptoms associated with the
mouth [39] may promote an organized collaborative
approach to these patients.
Bad breath
Mouth odor is one of the most common problems in
modern dentistry. Some patients complain of oral mal-
odor that is imperceptible to others. These patients are
considered to have halitophobia (delusional or psycho-
somatic halitosis). A related disorder, olfactory reference
syndrome (ORS), which is called “jikoshu-kyofu” in Japan,
is a condition in which a person mistakenly believes he or
she exudes an unpleasant odor [40, 41]. Phillips KA [42]
reported that 75 % of his ORS patients were preoccupied
with “bad breath”. These patients seem to actually have
halitophobia.
Halitophobic patients often visit dental offices to deter-
mine if their halitosis originates from dental problems.
Many investigations of patients with bad breath have
involved the removal of anaerobic microbes or volatile
Fig. 2 Panoramic radiograph of a patient with phantom bite
syndrome. This 70-year-old woman had been complaining of
occlusal dyscomfort and had visited various dentists for “bite
correction”, but had never finished the treatments
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sulfur compounds and have avoided the mental problems
of patients with halitophobia. Therefore, most dentists
only evaluate bacterial activity in the mouth and repeat-
edly clean the teeth and tongue. These procedures are not
essential for patients with halitophobia and are usually not
helpful.
Because halitophobic patients tend to pursue organic
causes of their bad breath, providing them with psycho-
logical treatment is very difficult. The patient interprets an
immediate psychiatric referral as a sign that the dentist
believes that the complaint is “psychogenic”: The patient
abruptly leaves the dentist and never visits the psychiatrist.
Ideally, the dentist can explain the need for treating the
psychosomatic aspects of the complaint and can prescribe
a selective serotonin reuptake inhibitor along with cogni-
tive therapy [43].
Halitophobia differs from other oral psychosomatic
disorders in two major respects. The first is that the
main aspect of the patient’s suffering is “taijin-kyofu”
(anthrophobia) rather than abnormal oral sensations.
Second, most halitophobic patients are adolescents.
Future treatment of these patients will require a new
clinical approach that is validated for effectiveness.
Management of dental patients with MUOS
Patients with the MUOS discussed in this review tend to
develop another symptom after their previous symptom
is ameliorated. Even with obvious improvement, these
patients never accept the evidence of improvement and
continue to complain of minimal residual symptoms.
Patients insist on unique treatment plans, never listen to
the advice of specialists, and make repeated requests
that the dentist perform as they planned, convinced it is
the best solution for their dental problems. Most den-
tists tire of refusing the patient’s request, which therefore
results in more dental treatment than is necessary.
Patients with MUOS may have underlying cognitive
distortions that cause them to continue to complain of
residual malfunction without regard to obvious improve-
ment as a result of treatment. Although the efficacy of
treatment with antidepressants is certainly important,
patient-dentist interactions are more critical [44]. Under-
standing the patient’s mental and oral status plus the use
of therapeutic techniques that take into account the
interactions between mind and mouth are essential to
psychosomatic dentistry.
Psychiatric referral is often difficult and usually not
helpful [4]. Such patients generally do not accept such
referrals. In addition, psychiatrists do not understand oral
complaints without a thorough knowledge on dentistry.
To make matters worse, psychiatrists also dislike patients
with persistent dental complaints, wanting no business
with them.
However, we have reported that approximately 20 to
30 % of patients with MUOS are thought to have actual
psychiatric conditions such as depression, bipolar disorder,
and severe obsessive-compulsive disorder. Dentists should
acquire sufficient training to be able to recognize these
mental disorders [45] so that patients can be referred to
the appropriate specialist.
Currently, these patients are shunted between dentists
and psychiatrists, who shift the responsibility to one
another. At least for the time being, it appears that den-
tists cannot proactively avoid treating patients with
MUOS.
Conclusions
Dentists have been struggling because of the increasing
prevalence of MUOS and have been asked to adopt a new
treatment approach and to leave behind “brainless dentis-
try” or “mindless dentistry”. In collaboration with specialists
in psychosomatic medicine, the pathophysiology of MUOS
should be investigated, with a focus on brain-mouth inter-
actions. The education of dentists who are able to treat not
only teeth, but also the patient’s psychosomatic oral dis-
comfort is an important priority.
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